Izoniazidă Arena

Isoniazid, the active ingredient in Izoniazidă Arena, is an antitubercular agent presented as a tablet for oral use. It is employed in the treatment of active tuberculosis and in preventive therapy for latent Mycobacterium tuberculosis infection in adults and children.

GNH USA supplies Izoniazidă Arena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for cross‑border procurement.

Isoniazid is used in the antituberculosis therapeutic pathway to eradicate Mycobacterium tuberculosis. - Active tuberculosis: contributes to bacterial killing and shortens treatment duration. - Latent tuberculosis infection: reduces risk of progression to active disease when given as preventive therapy. - Post‑exposure prophylaxis: administered to high‑risk contacts to prevent development of active tuberculosis.

Isoniazid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting: mild gastrointestinal discomfort. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Elevated liver enzymes: mild transaminase rise detectable on labs. - Rash or mild skin itching: occasional dermatologic reaction.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, jaundice, or hepatitis. - Acute hypersensitivity: fever, eosinophilia, or Stevens‑Johnson syndrome. - Severe peripheral neuropathy: disabling sensory loss requiring medical intervention.

When prescribing Isoniazid, clinicians should consider several safety measures to minimize risk. - Baseline liver assessment: obtain hepatic function tests before initiation. - Monitor hepatic function: repeat liver enzymes periodically, especially in patients >35 years or with alcohol use. - Vitamin B6 supplementation: co‑administer pyridoxine to prevent neuropathy. - Avoid use in known hypersensitivity: discontinue if severe allergic reaction occurs. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Isoniazid interacts with several medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Rifampicin: combined use increases hepatotoxic risk. - Pyrazinamide: concurrent therapy heightens liver enzyme elevations. - Certain antiretrovirals (e.g., efavirenz): may reduce isoniazid plasma levels.

Moderate Interactions (Monitor Closely): - Phenytoin: may increase metabolism, lowering isoniazid concentrations. - Carbamazepine: induces hepatic enzymes, potentially reducing efficacy. - Alcohol: additive hepatotoxic potential, requires careful monitoring.